JP2015510942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510942A5 JP2015510942A5 JP2015501823A JP2015501823A JP2015510942A5 JP 2015510942 A5 JP2015510942 A5 JP 2015510942A5 JP 2015501823 A JP2015501823 A JP 2015501823A JP 2015501823 A JP2015501823 A JP 2015501823A JP 2015510942 A5 JP2015510942 A5 JP 2015510942A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- amino
- bromo
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- -1 chloro, bromo, iodo Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- SXWMIXPJPNCXQQ-UHFFFAOYSA-N 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound C1CN(C)CCC1NC1=NC(NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C2C(=O)NC=C(Br)C2=N1 SXWMIXPJPNCXQQ-UHFFFAOYSA-N 0.000 claims 1
- KDVYCNXFRJQRHS-UHFFFAOYSA-N 8-bromo-4-[3-(3-fluorophenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound C1CN(C)CCC1NC1=NC(NC=2C=C(OC=3C=C(F)C=CC=3)C=CC=2)=C2C(=O)NC=C(Br)C2=N1 KDVYCNXFRJQRHS-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229910017464 nitrogen compound Inorganic materials 0.000 claims 1
- 150000002830 nitrogen compounds Chemical class 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CJYHTFKCKXIEPC-UHFFFAOYSA-N 8-bromo-4-[4-(3-fluorophenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6h-pyrido[4,3-d]pyrimidin-5-one;hydrochloride Chemical compound Cl.C1CN(C)CCC1NC1=NC(NC=2C=CC(OC=3C=C(F)C=CC=3)=CC=2)=C2C(=O)NC=C(Br)C2=N1 CJYHTFKCKXIEPC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 | |
| US61/614,274 | 2012-03-22 | ||
| PCT/US2013/032575 WO2013142382A1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510942A JP2015510942A (ja) | 2015-04-13 |
| JP2015510942A5 true JP2015510942A5 (enExample) | 2016-05-12 |
| JP6101341B2 JP6101341B2 (ja) | 2017-03-22 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501823A Active JP6101341B2 (ja) | 2012-03-22 | 2013-03-15 | 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (enExample) |
| EP (1) | EP2828259B1 (enExample) |
| JP (1) | JP6101341B2 (enExample) |
| KR (1) | KR102011770B1 (enExample) |
| CN (1) | CN104428298B (enExample) |
| AU (1) | AU2013235344B2 (enExample) |
| BR (1) | BR112014023460B1 (enExample) |
| CA (1) | CA2868156C (enExample) |
| CL (1) | CL2014002505A1 (enExample) |
| EA (1) | EA031267B1 (enExample) |
| ES (1) | ES2694223T3 (enExample) |
| IL (1) | IL234802B (enExample) |
| IN (1) | IN2014MN02082A (enExample) |
| MX (1) | MX360912B (enExample) |
| MY (1) | MY184858A (enExample) |
| NZ (1) | NZ700283A (enExample) |
| PL (1) | PL2828259T3 (enExample) |
| SG (1) | SG11201405942RA (enExample) |
| TR (1) | TR201816480T4 (enExample) |
| WO (1) | WO2013142382A1 (enExample) |
| ZA (1) | ZA201407588B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102228034B1 (ko) * | 2013-10-21 | 2021-03-16 | 제노스코 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
| ES2747249T3 (es) * | 2014-07-17 | 2020-03-10 | Sunshine Lake Pharma Co Ltd | Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR20170087913A (ko) * | 2014-11-17 | 2017-07-31 | 로드아일랜드하스피틀 | 나노물질, 조성물, 합성, 및 어셈블리 |
| BR112020026641A2 (pt) * | 2018-06-27 | 2021-03-30 | Oscotec Inc. | Derivados de piridopirimidinona para o uso como inibidores de axl |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| JP2025502748A (ja) | 2021-12-30 | 2025-01-28 | バイオメア フュージョン，インコーポレイテッド | Ｆｌｔ３の阻害剤としてのピラジン化合物 |
| EP4525873A1 (en) | 2022-05-17 | 2025-03-26 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433417A (zh) * | 2000-01-27 | 2003-07-30 | 沃尼尔·朗伯公司 | 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物 |
| CA2420286A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| CN100358892C (zh) * | 2000-08-31 | 2008-01-02 | 霍夫曼-拉罗奇有限公司 | 7-氧代吡啶并嘧啶 |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200938542A (en) * | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| ES2432414T3 (es) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| BR112012003661A2 (pt) * | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| ES2658290T3 (es) * | 2009-10-29 | 2018-03-09 | Genosco | Inhibidores de cinasa |
-
2013
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active Active
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en not_active Ceased
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
-
2014
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510942A5 (enExample) | ||
| AU2011215638B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| US20100168125A1 (en) | Indolizines and aza-analog derivatives thereof as cns active compounds | |
| JP2014521625A5 (enExample) | ||
| US9233961B2 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| WO2012080451A1 (en) | Imidazopyridines as respiratory syncytial virus antiviral agents | |
| US20110288301A1 (en) | Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity | |
| JP2013529196A5 (enExample) | ||
| JP2006523193A5 (enExample) | ||
| ES2701087T3 (es) | Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis | |
| WO2014151729A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2006523192A5 (enExample) | ||
| EP3209652A1 (en) | Tricyclic atropisomer compounds | |
| EP3328859A1 (en) | Respiratory syncytial virus inhibitors | |
| AU2002211827A1 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
| EP1325009A2 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| JP2005511643A5 (enExample) | ||
| RU2015118985A (ru) | Производные имидазопиридина | |
| HK1226725A1 (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis | |
| HK1226725B (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis | |
| AU2013202881A1 (en) | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction |